SHTPY (Schott Pharma AG KGaA) Risk Assessment


SHTPY Schott Pharma AG & CO KGaA SHTPY
64 GF Score
Price $4.37
GF Value $7.02
! 2 Warning Signs
View Full Analysis

What is Schott Pharma AG KGaA Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Schott Pharma AG KGaA is: No Data: Cannot be evaluated.

Schott Pharma AG KGaA  (OTCPK:SHTPY) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Schott Pharma AG KGaA Risk Assessment Related Terms

SHTPY vs ISRG, BDX, MDLN: Risk Assessment Comparison

For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Schott Pharma AG KGaA Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Schott Pharma AG KGaA's Risk Assessment falls into.


SHTPY
64GF Score
Schott Pharma AG & CO KGaA SHTPY
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?

Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued. The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.

Key valuation signals for SHTPY:

  • Risk Assessment:
  • GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Schott Pharma AG KGaA Business Description

Address Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score

Get the complete analysis for SHTPY

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.37
Price
$7.02
GF Value